Home>Topics>Stocks>Teva Pharmaceutical Industries

Teva Pharmaceutical Industries TEVA

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Genervon ALS drug shows encouraging results

      Headlines

      Mon, 20 Oct 2014

      ACOR ) (Pending: CVTS ) (NASDAQ: ACAD ) ( OTCQX:CYNAF ) (NASDAQ: IPXL ) ( OTCQB:TTNP ) ( OTCQB:SGTH ) (NYSE: TEVA ) (NASDAQ: ADMS ) (NASDAQ: PRAN ) (NASDAQ: CHTP ) (NASDAQ: PRTA ) (NASDAQ: FOLD ) (NASDAQ: AVNR ) (NYSE: BSX

    2. FDA clears Pfizer's abuse deterrent pain med

      Headlines

      Fri, 17 Oct 2014

      further assess the impact of the abuse-deterrent properties. Opioid-related tickers: ( ZGNX +1.9% )( EGLT +0.2% )( ACUR +2.3% )( MNK +4.1% )( ABBV +0.9% )( TEVA -0.8% )( ALKS +2.7% ) Post your comment!

    3. With Strong Corporate Partnerships, Xenon Pharmaceuticals IPO Looks Appealing

      Headlines

      Thu, 16 Oct 2014

      By Don Dion : Xenon Pharmaceuticals (Pending: XENE ) recently filed with the Securities and Exchange Commission (SEC) for an IPO with plans to list on NASDAQ. At a target high of $12 for 4 million + shares, the company can potentially raise nearly $55 million. The book runners of record are Wells

    4. Teva Review Raises Concerns and Mesoblast Marks Time; Fair Value Unchanged

      Commentary

      Thu, 16 Oct 2014

      Mesoblast partner Teva Pharmaceuticals has announced it will discontinue ..... failure, or CHF, partnered with Mesoblast. Teva expects to realise cost savings of approximately ..... period which will be redirected towards Teva 's core therapeutic areas of central nervous

    5. IPO Preview: Xenon Pharmaceuticals

      Headlines

      Thu, 16 Oct 2014

      diseases caused by mutations in ion channels, known as channelopathies. Genentech affiliate to purchase $5mm in concurrent private placement. Teva to purchase $10mm on the IPO, 23% Valuation Glossary Valuation Ratios Mrkt Complete Story »

    6. UPDATE 2-U.S. top court divided in battle over Teva MS drug patent

      Headlines

      Wed, 15 Oct 2014

      (Adds fresh details from oral argument, paragraphs 8-9, 11-12)

    7. U.S. Supreme Court justices divided over Teva patent battle

      Headlines

      Wed, 15 Oct 2014

      WASHINGTON, Oct 15 (Reuters) - The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug.

    8. Wall Street Breakfast: Chinese CPI Slips To Lowest In Almost 5 Years

      Headlines

      Wed, 15 Oct 2014

      By Wall Street Breakfast : Economy Chinese inflation dropped to an almost five-year low in September, tumbling to 1.6% on year from 2% in August and coming in below consensus of 1.7%. Factory gate prices (PPI) slumped 1.8% vs -1.2% previously. "You got falling oil prices, falling house prices, ...

    9. Teva due to appear in Supreme Court over Copaxone patent

      Headlines

      Wed, 15 Oct 2014

      is due to hear oral arguments today over a patent for Teva 's (NYSE: TEVA ) top-selling multiple sclerosis drug Copaxone, which ..... MYL ) and Natco. The companies risk having to pay Teva hundreds of millions of dollars if they introduce Copaxone

    10. U.S. top court hears Teva's multiple sclerosis drug patent fight

      Headlines

      Wed, 15 Oct 2014

      WASHINGTON, Oct 15 (Reuters) - The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of

    « Prev12345Next »
    Content Partners